Rice biotech studio secures investment from Modi Ventures, adds founder to board

fresh funding

RBL LLC has landed an investment from Houston-based Modi Ventures and named its founder, Sahir Ali (far left), to its board. Photo courtesy Rice University Biotech Launch Pad via LinkedIn

RBL LLC, which supports commercialization for ventures formed at the Rice University Biotech Launch Pad, has secured an investment from Houston-based Modi Ventures.

Additionally, RBL announced that it has named Sahir Ali, founder and general partner of Modi Ventures, to its board of directors.

Modi Ventures invests in biotech companies that are working to advance diagnostics, engineered therapeutics and AI-driven drug discovery. The firm has $134 million under management after closing an oversubscribed round this summer.

RBL launched in 2024 and is based out of Houston’s Texas Medical Center Helix Park. William McKeon, president and CEO of the TMC, previously called the launch of RBL a “critical step forward” for Houston’s life sciences ecosystem.

“RBL is dedicated to building companies focused on pioneering and intelligent bioelectronic therapeutics,” Ali said in a LinkedIn post. “This partnership strengthens the Houston biotech ecosystem and accelerates the transition of groundbreaking lab discoveries into impactful therapies.”

Ali will join board members like managing partner Paul Wotton, Rice bioengineering professor Omid Veiseh, scientist and partner at KdT Ventures Rima Chakrabarti, Rice alum John Jaggers, CEO of Arbor Biotechnologies Devyn Smith, and veteran executive in the life sciences sector James Watson.

Ali has led transformative work and built companies across AI, cloud computing and precision medicine. Ali also serves on the board of directors of the Drug Information Association, which helps to collaborate in drug, device and diagnostics developments.

“This investment by Modi Ventures will be instrumental to RBL’s growth as it reinforces confidence in our venture creation model and accelerates our ability to develop successful biotech startups,” Wotton said in the announcement. "Sahir’s addition to the board will also amplify this collaboration with Modi. His strategic counsel and deep understanding of field-defining technologies will be invaluable as we continue to grow and deliver on our mission.”

From Your Site Articles

Sentinel BioTherapeutics is developing cytokine interleukin-2 (IL-2) capsules to fight many solid tumors. Photo via Getty Images.

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.

Rice University opens biotech venture studio in TMC

rapidly scaling

In its mission to amplify and advance biotech innovation, Rice University has announced its latest initiative — a new lab focused on bringing life-saving medical technologies to commercialization.

Established to rapidly build companies based on Rice University's portfolio of over 100 patents, RBL LLC is a new biotech venture creation studio based in Texas Medical Center Helix Park. RBL comes on the heels of establishing the Rice Biotech Launch Pad, a biotech innovation accelerator that opened last year.

Paul Wotton, executive director of the Rice Biotech Launch Pad, co-founded RBL with his colleagues Omid Veiseh, Rice professor of bioengineering and faculty director of the Rice Biotech Launch Pad; Jacob Robinson, Rice professor of electrical and computer engineering; and Dr. Rima Chakrabarti, a physician scientist and venture capital investor with KdT Ventures.

“This is a pivotal moment for Houston and beyond,” Wotton, who serves as RBL’s managing partner, says in a news release from Rice. “Houston has rapidly emerged as a global life sciences powerhouse, blending cutting-edge research with early clinical applications at Rice and the city’s world-renowned hospital systems.

"Investors from across the nation are recognizing Houston’s potential, and with RBL, we’re building on that momentum," he continues. "We’ll not only amplify the work of the Rice Biotech Launch Pad but expand our reach across Texas, creating opportunities for biotech ventures statewide and driving growth for the biotech industry as a whole.”

Strategically located in TMC, RBL will collaborate with medical leaders, investors, corporations, and other players both in the same building and on the greater TMC campus.

“Leveraging Rice University’s Biotech Launch Pad breakthroughs and pairing it with the world-class translational infrastructure of TMC Helix Park well positions RBL to drive unprecedented advances in patient care,” William McKeon, president and CEO of the TMC, says in the release. “This partnership between academia, industry and health care is exactly what’s needed to transform medical discoveries into real-world solutions that improve lives globally.”

RBL is Rice's latest effort to bridge the gap between academia and biotech innovation, an effort led by Paul Cherukuri, Rice’s chief innovation officer, who reportedly spearheaded development of the new initiative.

“RBL is a game-changer for Rice, Houston and the global biotech community,” Cherukuri adds. “This venture not only accelerates the commercialization of our innovations but also sets a blueprint for other universities looking to maximize the real-world impact of their discoveries. By combining scientific expertise with entrepreneurial support from Day Zero together with strategic clinical partnerships in the TMC, we’re creating a model for driving large-scale biotech innovation that universities everywhere should aspire to replicate.”

Since the Rice Biotech Launch Pad was established, Motif Neurotech closed its series A round with an oversubscribed $18.75 million, the hub secured a $34.9 million grant, and a “living pharmacy” founded at the Launch Pad received industry validation.

“RBL provides a powerful platform to translate high-impact scientific discoveries into therapies that will dramatically improve patient outcomes,” Veiseh says. “Our goal is to rapidly bring Rice’s pioneering research into the clinic, delivering life-saving solutions to patients around the world.”

Ad Placement 300x100

Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Here's how Houston ranks among the best U.S. cities to start a career

New Horizons

College graduates staying in Houston are in the right place to be, according to a new WalletHub study. Houston has emerged on a new list of the 100 best places in America for starting a career.

Houston ranked 51st out of 182 U.S. cities based on its quality of life and vast opportunities for new college graduates transitioning into the workforce. The study compared each city based on 25 relevant metrics, like the availability of entry-level jobs, each city's annual job growth rate, workforce diversity, median annual income, housing affordability, and others.

Atlanta, Orlando, and Austin respectively comprised the top three best places to start a career.

Houston ranked 48th overall for its quality of life, and appeared No. 51 for its professional opportunities for new college graduates. Whether its starting a new business or entering a high-earning job field, Houston has many more opportunities than the vast majority of other cities on the list.

"The best cities for starting a career not only have a lot of job opportunities but also provide substantial income growth potential and satisfying work conditions," said WalletHub analyst Chip Lupo. "It’s also important to consider factors such as how fun a city is to live in or how good of a place it is for raising a family, to ensure life satisfaction outside of your career."

Other Texas hotspots for early career professionals
Austin boasts the best quality of life out of all 182 cities in the report, and the 10th best professional opportunities. The state capital also outperformed all other U.S. cities with the highest monthly average starting salaries for early career workers after being adjusted for the city's cost of living. Austin also offers the 15th highest number of entry level jobs per capita, the report said.

In a separate comparison of the cities with the largest share of residents aged 25 to 34, Austin ranked No. 5 nationally.

"In addition, Austin’s median annual household income is the 10th-highest in the nation, providing strong earning potential for those starting a career or a business," the report said. "Austin is also the sixth best city for singles, offering a vibrant social scene alongside strong career opportunities for young professionals."

Elsewhere in Texas, Dallas ranked as the second-best city in Texas for new grads to start a career and 12th nationally. Additional cities that made it into the top 100 best U.S. cities for early career professionals include Plano (No. 32), Irving (No. 42), Fort Worth (No. 64), Amarillo (No. 73), and San Antonio (No. 85).

The top 10 best cities for starting a career are:

No. 1 – Atlanta, Georgia
No. 2 – Orlando, Florida
No. 3 – Austin, Texas
No. 4 – Tampa, Florida
No. 5 – Miami, Florida
No. 6 – Charleston, South Carolina
No. 7 – Pittsburgh
No. 8 – Knoxville, Tennessee
No. 9 – Salt Lake City, Utah
No. 10 – Columbia, South Carolina

---

This article first appeared on CultureMap.com.

Persona AI teams with Under Armour to protect next-gen robots

Future Fabrics

Houston-based Persona AI has cemented a partnership with sportswear manufacturer Under Armour to provide materials to protect future robots operating in dangerous conditions.

Through the partnership, Persona AI and Under Armour will launch a research initiative to explore whether advanced performance textiles can improve the durability and resilience of humanoid robots operating in harsh industrial environments.

“This is an opportunity to apply our innovation expertise in a new context,” Kyle Blakely, senior vice president of innovation, design studio, development, and testing at Under Armour, said in a news release. “Robotics presents a fascinating new design challenge, and we aim to play a leading role in shaping performance solutions for these environments. As humanoid systems take on more physically demanding roles, we see real potential to create new market opportunities, and we’re exploring how concepts like thermal management, abrasion resistance, and ﬂexibility translate beyond sport."

Founded in June 2024 by former NASA engineer Nicolaus Radford and former Figure AI CTO Jerry Pratt, Persona AI has quickly risen to be a top name in the development of humanoid robotic systems. Radford previously was the principal investigator at NASA’s Dexterous Robotics Lab before becoming CEO of Nauticus Robotics. While at NASA, he was the chief engineer behind Robotnaut 2, the first humanoid robot on the International Space Station.

Persona AI raised preseed funding to develop humanoid robots designed to operate in shipyards and other industrial sites. The company has inked partnerships with HD Korea Shipbuilding & Offshore Engineering, HD Hyundai Robotic, and Korean manufacturing firm Vazil Company to create and deploy humanoid robots for complex welding tasks in shipyards.

These environments often involve exposure to dangerous chemicals, harsh weather and other potential hazards. The partnership between Persona AI and Under Armour will combine the clothing manufacturer’s development of resilient but flexible materials with the humanoid design of Persona AI.

Though best known for its sportswear, Under Armour produces a wide range of specialist fabrics and clothing, including an entire line used by the U.S. military. The company’s track record of developing high-performance fabrics built to withstand war zones and desert conditions makes it a strong partner in Persona AI’s latest endeavor.

“We chose to work with Under Armour because of their track record of innovation with these types of performance materials,” Radford said. “As we develop humanoids for intense and potentially hazardous environments, this collaboration helps us understand how advanced materials can enhance long-term reliability, thereby informing solutions to better protect workers in the ﬁeld.”

Waymo suspends robotaxi service in Houston due to weather concerns

Transportation news

Waymo has suspended driverless car services in Houston and other major Texas cities, and in Atlanta, after one of its vehicles was stranded by flooding during heavy rains that will likely also hinder travel in a large swath of the U.S over the holiday weekend.

Severe thunderstorms with large hail and gusty winds were possible Friday, May 22 in Texas and other parts of the Southern and Central Plains, the National Weather Service said.

Forecasters warned of possible flash flooding along the Gulf Coast of Texas and Louisiana on Saturday, when rain and thunderstorms were expected across much of the central and eastern U.S.

The Waymo vehicle got stuck during a downpour in Atlanta on Wednesday that flooded streets and even part of a downtown highway. The vehicle was not occupied and was later recovered, the company said in a statement. At least one other Waymo vehicle was waylaid during the storm.

Waymo serves only the city of Atlanta in Georgia, and services Dallas, Houston, Austin, and San Antonio in Texas.

The company paused service in Texas “out of an abundance of caution for the forecasted severe weather,” the statement said.

View All Listings

INNOVATIONMAP EMAILS ARE AWESOME